For how we live.
In the investigator-led Danish DALIAH trial, pegylated interferon-alfa and hydroxyurea produced similar molecular responses by intention-to-treat, but far more patients stopped interferon.
A 100-child randomized trial in Uganda found a cheap supplement lowered infection rates on top of standard hydroxyurea therapy — though the authors say it needs a bigger trial before it changes practice.
A modelling analysis puts 2.75 million children under five in sub-Saharan Africa living with sickle cell disease. Seven African countries have transplant programmes; approved gene therapies cost millions.